Autologous Transplant To End NMO Spectrum Disorder
Public ClinicalTrials.gov record NCT03829566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.
Study identification
- NCT ID
- NCT03829566
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Rituximab Drug
- Cyclophosphamide Drug
- Mesna Drug
- rATG Drug
- Methylprednisolone Drug
- G-CSF Drug
- IVIg Biological
- Autologous Stem Cells Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2019
- Primary completion
- Dec 31, 2024
- Completion
- Nov 27, 2025
- Last update posted
- Nov 19, 2019
2019 – 2025
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University, Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Neuromyelitis Optica trials
Other public records listing Neuromyelitis Optica. Sorted by last update posted; newest first. Not a recommendation.
- NCT05982925: Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders Recruiting
- NCT00716066: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Active, not recruiting
- NCT01623076: The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Active, not recruiting
- NCT00445367: Biobank For MS And Other Demyelinating Diseases Active, not recruiting
- NCT06398158: Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder Recruiting
- NCT05566769: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03829566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2019 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03829566 live on ClinicalTrials.gov.